We are live on ! Find out more
HM

HealthCor Management Portfolio holdings

AUM $109M
1-Year Est. Return 10.64%
This Fund
S&P 500
This Quarter Est. Return
+11.62%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.87B
AUM Growth
+$212M
Cap. Flow
+$49.5M
Cap. Flow %
2.65%
Top 10 Hldgs %
45.13%
Holding
78
New
31
Increased
13
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$75M
2
AGN
Allergan plc
AGN
+$50M
3
AGN
Allergan Inc
AGN
+$48.9M
4
ABBV icon
AbbVie
ABBV
+$46.5M
5
BEAM
BEAM INC COM STK (DE)
BEAM
+$46.5M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$64.6M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$62M
3
MDRX
Veradigm Inc. Common Stock
MDRX
+$58.8M
4
MDCO
Medicines Co
MDCO
+$51.5M
5
CFN
CAREFUSION CORPORATION
CFN
+$49.7M

Sector Composition

Rank Sector Weight
1 Healthcare 63.15%
2 Financials 6.73%
3 Consumer Staples 6.5%
4 Materials 1.82%
5 Real Estate 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
26
Alkermes
ALKS
$8.22B
$27.7M 1.49%
825,000
– –
PCYC
27
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$27.7M 1.48%
+200,000
New +$22.2M
IPXL
28
DELISTED
Impax Laboratories, Inc.
IPXL
$22.8M 1.22%
1,112,400
+286,100
+35% +$5.91M
MCK icon
29
McKesson
MCK
$100B
$22.2M 1.19%
+173,218
New +$21.3M
ZTS icon
30
Zoetis
ZTS
$32.4B
$21M 1.13%
+675,000
New +$20.7M
EL icon
31
Estee Lauder
EL
$30.4B
$21M 1.12%
+300,000
New +$20.3M
DVAX
32
DELISTED
Dynavax Technologies
DVAX
$20.9M 1.12%
1,760,000
– –
ACOR
33
DELISTED
Acorda Therapeutics
ACOR
$18.8M 1.01%
4,583
+1,235
+37% +$5.32M
CYNO
34
DELISTED
Cynosure, Inc. Class A
CYNO
$16.5M 0.89%
725,000
+125,000
+21% +$3.11M
SLXP
35
CALL
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$16.4M 0.88%
+245,300
New +$16.9M
PTCT icon
36
PTC Therapeutics
PTCT
$5.64B
$15.7M 0.84%
+732,200
New +$12.7M
CLVS
37
DELISTED
Clovis Oncology, Inc.
CLVS
$15.6M 0.83%
256,021
+131,021
+105% +$9.29M
ELV icon
38
Elevance Health
ELV
$81.5B
$14.6M 0.78%
+175,000
New +$15M
WBMD
39
DELISTED
WebMD Health Corp.
WBMD
$12.8M 0.69%
+450,000
New +$14M
NVAX icon
40
Novavax
NVAX
$1.2B
$11M 0.59%
+174,900
New +$9.85M
CLDX icon
41
CALL
Celldex Therapeutics
CLDX
$2.99B
$10.6M 0.57%
+20,000
New +$6.86M
NUVA
42
DELISTED
NuVasive, Inc.
NUVA
$10.4M 0.56%
425,000
-1,025,000
-71% -$25.2M
SRPT icon
43
PUT
Sarepta Therapeutics
SRPT
$1.57B
$9.45M 0.51%
+200,000
New +$7.7M
RGLS
44
DELISTED
Regulus Therapeutics
RGLS
$9.19M 0.49%
+8,125
New +$9.59M
CRVL icon
45
CorVel
CRVL
$3.06B
$8.06M 0.43%
654,000
-1,616,766
-71% -$18.2M
CCEP icon
46
Coca-Cola Europacific Partners
CCEP
$48.3B
$8.04M 0.43%
+200,000
New +$7.62M
EXEL icon
47
Exelixis
EXEL
$13.3B
$7.31M 0.39%
+1,255,350
New +$6.5M
SRPT icon
48
CALL
Sarepta Therapeutics
SRPT
$1.57B
$7.08M 0.38%
+150,000
New +$5.78M
PFE icon
49
Pfizer
PFE
$143B
$6.76M 0.36%
+248,217
New +$6.75M
CMRX
50
DELISTED
Chimerix, Inc.
CMRX
$6.59M 0.35%
300,000
-183,072
-38% -$3.77M
1
2
3 4

Similar funds

IA
Integrity Advisory Overland Park, Kansas $109M AUM 15.71% 1-Year Est. Return
EPC
Emerson Point Capital Larchmont, New York $108M AUM 19.03% 1-Year Est. Return
TCMV
Technology Crossover Management VII Menlo Park, California $107M AUM 51.05% 1-Year Est. Return
SI
Salesforce Inc San Francisco, California $114M AUM 53.18% 1-Year Est. Return
HCWM
Harrison & Co Wealth Management Roanoke, Virginia $103M AUM 9.82% 1-Year Est. Return
PC
Phoenician Capital New York $117M AUM 9.46% 1-Year Est. Return
RF
Resolute Financial Newburyport, Massachusetts $118M AUM 11.75% 1-Year Est. Return
AWM
Align Wealth Management Oklahoma City, Oklahoma $118M AUM

HealthCor Management's Q3 2013 Portfolio in Review

As of Q3 2013, HealthCor Management held 78 positions worth $1.87B, up 13% from $1.65B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

HealthCor Management's Q3 2013 filing shows 31 new, 13 increased, 11 reduced and 20 closed positions. Its largest new stake was Zimmer Biomet: 952,750 shares worth $76M. The largest sale was Biogen, an estimated $64.6M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 71% a quarter earlier, followed by Financials and Consumer Staples.

  • HealthCor Management's largest Q3 2013 buy was Zimmer Biomet: 952,750 shares worth $76M.
  • HealthCor Management added most to Aegerion Pharmaceuticals in Q3 2013, an estimated $25.3M increase.
  • HealthCor Management's biggest Q3 2013 reduction was Veradigm Inc. Common Stock, cutting an estimated $58.8M.
  • HealthCor Management fully exited Biogen in Q3 2013, selling an estimated $64.6M.
  • HealthCor Management's ten largest holdings make up 45% of its $1.87B portfolio in Q3 2013.
  • HealthCor Management opened 31 new positions and closed 20 in Q3 2013.
  • HealthCor Management's portfolio value rose 13% quarter-over-quarter to $1.87B.

Based on HealthCor Management's 13F filing for Q3 2013, filed 14 Nov 2013.